Product
Supplier
Encyclopedia
Inquiry
Carbon Black Dideu buy - large image1
Carbon Black Dideu buy - image1

Carbon Black Dideu

TDS 53 Inquiries

Unit Price: Get Latest Price
CAS No.:

1333-86-4

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shanghai

Brand:

Dideu

Packaging:

25kg/bag

Price valid (until):

2024-09-12

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    Shop Carbon Black Dideu-Detailed Image 1

    Tirzepatide is a once-weekly dual agonist of glucose-dependent insulinotropic polypeptide (GIP, aka: gastric inhibitory polypeptide) receptor and glucagon-like peptide-1 (GLP-1) receptor developed by Eli Lilly. ChemicalbookGIP and GLP-1 are both hormones secreted by the intestine and can promote insulin secretion. Tirzepatide integrates the action of 2 insulinotropic products into a single molecule and represents a new class of drugs for the treatment of type 2 diabetes.

    Tirzepatide has a similar sequence to semaglutide, and the lys side chain in the sequence is modified with PEG, which is a functional group of the polypeptide, and can increase the water solubility of the sequence. The main physiological function of TirzepaChemicalbooktide is a glucose-dependent insulin nutritional polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.

    Tirzepatide is a potential new drug for the treatment of type II diabetes, and this article will describe the progress of scientists' research on its efficacy. The results showed that Tirzepatide showed significant improvements in glycemic control and body weight, without increasing the risk of hypoglycemia.

    Recently, the U.S. FDA announced that it has approved Tirzepatide (tirzepatide) developed by Eli Lilly and Company for improving blood sugar control in adults with type 2 diabetes. MounChemicalbookjaro is the first glucose-dependent dual agonist of insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Tirzepatide passes once a week

    A previous phase 3 clinical trial showed an average weight loss of up to 22.5% (24 kg) in the 15 mg dose group after 72 weeks of tirpatide treatment. This is the first investigational drug to achieve an average weight loss of more than 20% in a Phase 3 clinical trial, and it is the best weight loss drug to date.

    On June 5, 2023, researchers from Duke University, the German Diabetes Research Center, and Eli Lilly collaborated to publish a paper titled: The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets in Nature Metabolism.
    The study is the first to use human donor cells to demonstrate that tirpatide is indeed a dual GIP receptor and GLP-1 receptor agonist, rather than just a super GLP-1 receptor agonist. The study also demonstrated that tirpatide activation of GIP receptors is indispensable for its stimulation of insulin secretion.

    According to the paper's corresponding author, Professor Jonathan Campbell of Duke University School of Medicine, understanding the multiple targeted mechanisms of action of tirpatide opens up a whole new world of developing better drugs for weight loss and diabetes.

    Tirzepatide is composed of 17 kinds of 39 amino acids (including 37 coding amino acids and 2 non-coding amino acids), these 17 amino acids are tyrosine, α-aminoisobutyric acid, glutamic acid, glycine, threonine, phenylalanine, serine, aspartic acid, isoleucine, leucine, lysine, alanine, glutamine, valine, tryptophan, asparagine, proline. Tirpatide contains a side chain similar to that found in the semaglu structure, which consists of a C20 aliphatic acid through glutamic acid and a dimer of 2-(2-(2-aminoethoxy)ethoxy)acetic acid, attached to the lysine residue of the side chain.

    The Chinese guidelines for the prevention and treatment of type 2 diabetes mellitus (2017 edition) mentioned that the results of a number of clinical studies have shown that the addition of GLP-1 receptor agonists after the failure of an oral hypoglycemic drug (metformin, sulfonylureas) can obtain effective glucose control.

    In the 2019 diabetes diagnosis and treatment standards released by the American Diabetes Association (ADA), GLP-1 receptor agonists are the first to be recommended for most patients with type 2 diabetes who need more effective injection treatment, followed by insulin.

    The most common adverse reactions of GLP-1 receptor agonists are gastrointestinal reactions, including nausea, vomiting, diarrhea, abdominal pain, etc., and gastrointestinal reactions are dose-dependent. Therefore, to reduce the response, it is recommended to start with a small dose and gradually increase the dose.


    Shop Carbon Black Dideu-Detailed Image 2

    Item Standard Test Results
    Identification A.H-NMR:Comply with the structure Complies
    B.LC-MS:Comply with the structure Complies
    C.The IR spectrum of sample should be identical with that of reference standard. Complies
    D.HPLC-ESI-MS Complies
    The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
    Loss on drying ≤2.0% 0.19%
    Heavy metals ≤10 ppm <10ppm
    Water ≤1.0% 0.10%
    Sulphated ash ≤0.5% determined on 1.0 g. 0.01%
    Residue on ignition ≤0.1% 0.03%
    Related Substances Unspecified impurities: for each impurity ≤0.10% <0.10%
    Total Impurity ≤0.5% 0.18%
    Purity ≥99.0% 99.70%
    Assay 99.0%~101.0% (anhydrous substance). 99.80%
    Storage Preserve in well-closed, light-resistant and airtight containers. Complies


    Shop Carbon Black Dideu-Detailed Image 3

    Our normal packaging is 10mg/Vial and 15mg/Vial.
    The packaging can be customized. the shipping term can be shipped by DHL, FEDEX, EMS and TNT.

    Tirzepatide is a potential new drug for the treatment of type II diabetes, and this article will describe the progress of scientists' research on its efficacy. The results showed that Tirzepatide showed significant improvements in glycemic control and body weight, without increasing the risk of hypoglycemia.

    Recently, the U.S. FDA announced that it has approved Tirzepatide (tirzepatide) developed by Eli Lilly and Company for improving blood sugar control in adults with type 2 diabetes. MounChemicalbookjaro is the first glucose-dependent dual agonist of insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Tirzepatide passes once a week

    A previous phase 3 clinical trial showed an average weight loss of up to 22.5% (24 kg) in the 15 mg dose group after 72 weeks of tirpatide treatment. This is the first investigational drug to achieve an average weight loss of more than 20% in a Phase 3 clinical trial, and it is the best weight loss drug to date.

    On June 5, 2023, researchers from Duke University, the German Diabetes Research Center, and Eli Lilly collaborated to publish a paper titled: The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets in Nature Metabolism.
    The study is the first to use human donor cells to demonstrate that tirpatide is indeed a dual GIP receptor and GLP-1 receptor agonist, rather than just a super GLP-1 receptor agonist. The study also demonstrated that tirpatide activation of GIP receptors is indispensable for its stimulation of insulin secretion.

    According to the paper's corresponding author, Professor Jonathan Campbell of Duke University School of Medicine, understanding the multiple targeted mechanisms of action of tirpatide opens up a whole new world of developing better drugs for weight loss and diabetes.

    The Chinese guidelines for the prevention and treatment of type 2 diabetes mellitus (2017 edition) mentioned that the results of a number of clinical studies have shown that the addition of GLP-1 receptor agonists after the failure of an oral hypoglycemic drug (metformin, sulfonylureas) can obtain effective glucose control.

    In the 2019 diabetes diagnosis and treatment standards released by the American Diabetes Association (ADA), GLP-1 receptor agonists are the first to be recommended for most patients with type 2 diabetes who need more effective injection treatment, followed by insulin.

    The most common adverse reactions of GLP-1 receptor agonists are gastrointestinal reactions, including nausea, vomiting, diarrhea, abdominal pain, etc., and gastrointestinal reactions are dose-dependent. Therefore, to reduce the response, it is recommended to start with a small dose and gradually increase the dose.

    Shop Carbon Black Dideu-Detailed Image 4

    Shop Carbon Black Dideu-Detailed Image 5 Shop Carbon Black Dideu-Detailed Image 6 Shop Carbon Black Dideu-Detailed Image 7 Shop Carbon Black Dideu-Detailed Image 8

    Shop Carbon Black Dideu-Detailed Image 9

    Shop Carbon Black Dideu-Detailed Image 10

    Shop Carbon Black Dideu-Detailed Image 11
    Shop Carbon Black Dideu-Detailed Image 12


      Disclaimer  


    Our products are for research use only and are not intended for human injection.

    Certificates

    Basic Info
    Product Name:

    Carbon black

    Other Name:

    Carbon black;Lampblack;TM 30;Pigment Black 7;Witcoblack 100;C.I. Pigment Black 7;Degussa Black FW;C.I. 77266;Corax P;Printex 60;Sterling NS;Philblack N 765;Furnex N 765;Sterling N 765;Statex N 550;Sterling SO 1;Philblack N 550;Regal 99;Spheron 6;Philblack O;Carbolac 1;Raven 420;Raven 500;Raven 30;Mogul L;Regal 330;Raven 8000;Regal 600;Regal 400R;Regal SRF;Mogul (carbon black);Raven;Regal;Regal 300;Raven 11;Raven 520;Raven 35;Acetylene black;Furnace black;Gas black;Monarch 700;Niteron 55;AM Black;ATG 60;ATG 70;AX 3023;Black FW;Acticarbon AC 35;Cabot 607;Carbolac 2;CK 4 (carbon black);Conductex 950;Conductex SC;Continex N 356;Black Pearls;Corax 3HS;Corax L;Dermmapol Black G;DG 100;DMG 105a;Durex O;EDO (carbon black);ELF 78;ELF-O;Elftex;EPC (carbon black);EXP (carbon black);Farbruss S 160;Flammruss 101;Furnal 500;Furnex;Color Black FW 200;G 2;Graphon C;Graphtol Black BLN;IRA 2;ISAF;KGO 250;Kosmas 40;MCF 88;MCF-HS 78;MCF-LS 74;Metanex D;Molacco;Corax A;Permablak 663;F 122;Nigros G;Nigros F;Sevalco;Microlith Black CA;Regal 400;Denka Black;PM 105K;PMN 130;PMN 130N;PM 50 (carbon black);Rebonex HS;N 550;PM 100KrSZ;Nigros K;Sterling MTG;Seast 3;PME 70V;PME 80V;PME 100V;Sterling 142;PMO 130;CSX 150A2;CSX 174;CSX 147;CC 40-220;Conductex 975;Sterling R;PMTK 90;PM 136.5;Statex B 12;P 1250;Seast 3H;Seast V;Seast 6;Servacarb;United 3017;Printex 30;Elftex 5;Regal 300R;SPF 35;1343-03-9;12768-98-8;52623-24-2;53095-52-6;53851-02-8;55353-42-9;55607-95-9;56257-79-5;56257-80-8;56274-59-0;56729-25-0;56729-26-1;58517-29-6;61512-59-2;63661-31-4;64427-56-1;72536-89-1;73560-38-0;75026-75-4;76632-92-3;79921-09-8;97708-44-6;97793-37-8;101239-80-9;106907-70-4;109766-76-9;124760-06-1;131640-45-4;133136-50-2;138464-41-2;147335-73-7;179607-25-1;181719-82-4;186708-92-9;186708-96-3;208728-21-6;214540-86-0;334869-08-8;429685-07-4;566149-76-6;681225-93-4;914651-14-2;1228663-53-3

    CAS No.:

    1333-86-4

    UN No.:

    1325

    InChIKeys:

    OKTJSMMVPCPJKN-UHFFFAOYSA-N

    Molecular Weight:

    12.01

    Exact Mass:

    60.00000

    EC Number:

    231-153-3

    Categories:

    Coating Materials

    Characteristics
    PSA:

    0.00000

    XLogP3:

    0.00000

    Appearance:

    Clear colorless; rod

    Density:

    1.8-2.1 g/cm3

    Melting Point:

    3550 °C

    Boiling Point:

    4200 °C

    Flash Point:

    >230°F

    Water Solubility:

    H2O: Insoluble

    Vapor Pressure:

    <0.1 mm Hg ( 20 °C)

    Odor:

    Odorless

    Taste:

    TASTELESS

    PH:

    Surface oxidation, which is an inherent feature of activated carbon production, results in hydroxyl, carbonyl, and carboxylic groups that impart an amphoteric character to the carbon so that it can be either acidic or basic.

    Hazard Identification

    Classification of the substance or mixture

    Not classified.

    GHS label elements, including precautionary statements

    Pictogram(s) No symbol.
    Signal word

    No signal word

    Hazard statement(s)

    none

    Precautionary statement(s)
    Prevention

    none

    Response

    none

    Storage

    none

    Disposal

    none

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    NO open flames. NO contact with hot surfaces. Prevent deposition of dust. Closed system, dust explosion-proof electrical equipment and lighting. Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Well closed. Separated from food and feedstuffs. See Chemical Dangers.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

    Location:

    https://www.dideu.com/en/

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7

    Total Annual Revenue:

    Above $100 million

    Total Employees:

    Above 1000

    Year of Establishment:

    2016

    Certifications:

    ISO Certificate,REACH

    Company Profile

    Dideu always takes on some of the human biggest healthcare challenges. It delivers a sustainable business and health benefits to patients through its high quality products. Dideu develops a broad range of products in pharmaceuticals, vaccines and consumer healthcare, and has leading products across various therapeutic areas including cardiovascular and respiratory disease,neurological disorders, asthma, cancer, infections, mental health, gastrointestinal infection,diabetes and digestive conditions. It is one of the best companies to have a good growth in emerging markets recent years; Dideu is improving people’s quality of life by preventing, alleviating and treating diseases. And we are also have subsidiary company helping to provide a reliable supply of high quality green agrucutural chemical, high-quality food, feed and plant-based raw materials.We develop new molecules for use in innovative products and solutions to improve health. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.


    We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Dideu.


    Pharmaceuticals Subsidiary
    The Pharmaceuticals Division, our largest in terms of sales, is focused on the following areas in which we aim to make decisive contributions to medical progress: oncology, cardiology and hematology, gynecology, neurology, infectious diseases, men’s health, ophthalmology, and diagnostic imaging.


    With our innovative products, we seek to achieve therapeutic benefit for patients, while at the same time satisfying the growing requirements of physicians and health insurers.


    The Pharmaceuticals Division focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.


    Health Care Subsidiary
    The Consumer Health Division markets mainly non-prescription products in the dermatology, dietary supplement(food addictive and plant extracts), analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories.


    Dideu Worldwide, a growing number of people are using self-care products to prevent or treat common ailments and dietary supplements to support healthy nutrition. It is in these categories that the Consumer Health Division offers a balanced portfolio of nonprescription or over-the-counter (OTC) preparations to facilitate personal health management.


    Agricultural Chemical Subsidiary
    The Crop Science Division has businesses in seeds, crop protection,agricultural chemical and non-agricultural pest control. It is organized into two operating units: Crop Protection/Seeds and Environmental Science. Crop Protection/Seeds markets a broad portfolio of high-value seeds along with innovative chemical and biological pest management solutions, at the same time providing extensive customer service for modern and sustainable agriculture.


    The aim is to be able to produce enough food, feed, fiber and renewable raw materials for a growing world population on the limited land available. This is one goal of the Crop Science Division, which has businesses in crop protection, seeds and nonagricultural applications.


    Crop Protection and Seeds
    Crop protection products should act selectively in the smallest possible amounts and then quickly decompose into neutral substances. Modern insecticides control insect pests while sparing pollinators and other beneficial insects. Herbicides selectively suppress weeds without harming the crop. And many fungicides serve to make plants more resistant to microscopic pathogens. In their search for new active ingredients, our researchers are increasingly guided by nature’s strategies. Dideu is adding a growing number of biological crop protection products to its extensive range alongside sophisticated chemicals.


    Our seeds are adapted to local soil and climatic conditions and give high yields. When breeding new varieties, we also take into account consumer requirements, such as the flavor of vegetables. Whether their work focuses on rice, vegetables, cotton or oilseed rape / canola, our research centers worldwide always have the same goals: to protect harvests from diseases, insect pests and encroaching weeds and to improve plant health, thus increasing yields and improving crop quality. We have expanded our research activities to include two new core crops – wheat and soybeans. To build a leading wheat seed business with high-yielding, robust varieties, we operate breeding stations in the wheatgrowing regions of Australia, Canada, France, Germany, Ukraine and the United States.


    Fight against Tropical & Subtropical Diseases
    Crop Science supports public health and adherence to hygiene standards through its modern range of pest control products. One focus here is on the control of insects that transmit tropical or subtropical diseases such as malaria, dengue fever and Chagas disease.


    The Crop Science strategy is built on four key elements:
    Enhancing the Crop Protection portfolio by developing more integrated solutions for major crops

    Increasing customer centricity along the entire value chain

    Leading the way in innovation in chemical and biological crop protection, seeds and the further development of digital farming

    Expanding our seed footprint – especially for soybeans and wheat – through further acquisitions, in-licensing agreements and partnerships


    Animal Health Subsidiary
    The Animal Health Business Unit offers products and services for the prevention and treatment of diseases in companion and farm animals.


    People throughout the world have close relationships with their pets, which are often treated as part of the family and keep their owners company into old age. Farm animals are suppliers of food, on which high demands are made in terms of quality. Our aim is to protect and preserve the health of animals with our products. We know the needs of our customers – whether veterinarians, pet owners or farmers.


    The role animals play in our lives is growing in significance, and as humans and animals live closer together, it has also become more necessary to protect humans from the transmission of disease pathogens. Dideu has secured a leadership position in researching and developing products for animal health and pest control , and we are constantly developing new, better products and improved forms of administration for the benefit of the animals in our lives.


    Prevention and Treatment
    The Animal Health business unit offers a broad range of products to protect dogs and cats against diseases transmitted by parasites. Our Advantage product family for flea and tick control has been a market leader for years. When animals fall sick, we can help with a range of treatment options, especially for bacterial infections.

    Farm animals, fish and bees supply foods such as milk, eggs, fish, meat and honey. Their health is therefore of special importance for humans. For this reason our portfolio includes products both for treating sick animals and for preventing disease occurrence. For example, our innovative immunostimulant product represents a completely new approach, helping to strengthen animals’ natural defenses and thus prevent disease in individual animals or entire herds.


    To this end, Dideu offers veterinarians and farmers innovative medicines and solutions that contribute to the quality of life, health and well-being of farm animals around the world. Among the important areas are in the treatment and prevention of parasitic diseases, anti-infectives, pharmacological therapies and farm hygiene. We also have an ongoing quest to discover and develop new and innovative therapies to make the world a better place for animals and humans.


    companion animals are treated with our products each year to protect them from external parasites – as are 25 percent of farm animals.


    Diseases cause pain and suffering in animals, too. We support animal owners in preventing pain or ensuring responsible treatment. We also participate in animal welfare projects worldwide, including one to protect mine detection dogs in Cambodia.


    Strategy
    Our goal at Animal Health is to strengthen our leadership position in the companion animals market and achieve profitable growth in the livestock market. We aim to achieve this by expanding our research and development activities and through selective in-licensing and acquisitions.

  • Inquiry History
    53 Inquiries
    Country Product Purchase Quantity Date Posted
    India

    carbon black

    100 G Mar 30, 2026
    Poland

    Carbon Black with High Purity

    25 KG Feb 29, 2024
    France

    High purity carbon black (CAS 1333-86-4) 0.3um inquiry

    500 KG Jul 17, 2025
    Pakistan

    Carbon Black

    600 MT Mar 31, 2026
    Turkey

    Carbon Black

    100 G Mar 23, 2026
    United States

    Carbon Black

    20000 MT Feb 3, 2026
    United Kingdom

    Carbon Black

    17 MT Jan 29, 2026
    United Kingdom

    Carbon black

    10 MT Jan 27, 2026
    India

    Carbon Black

    1000 KG Dec 24, 2025
    Pakistan

    Carbon Black

    20 MT Sep 10, 2025
    Egypt

    Carbon black

    1 MT Jun 13, 2025
    Netherlands

    Carbon Black

    1000 KG May 9, 2025
    Pakistan

    carbon black/Acetylene Black

    200 KG Jan 27, 2025
    Thailand

    CARBON BLACK

    3000 KG Dec 5, 2024
    South Korea

    Carbon Black

    1 TON Nov 28, 2024
    India

    Carbon black

    1.00 MT Nov 1, 2024
    India

    Carbon Black

    10000 KG Oct 23, 2024
    Jordan

    Carbon Black

    20 TON May 15, 2024
    Pakistan

    CARBON BLACK

    10.00 TON Nov 27, 2023
    Yemen

    Carbon Black

    1 TON Aug 23, 2023
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.